Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE/no PQC reported; patient received the first dose of GARDASIL 9 in October 2022. The pharmacist received a prescription for the second dose recently; This Spontaneous report was received from a pharmacist and referred to a 36 -year-old patient of unknown gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. In in October 2022, the patient was vaccinated with the first dose of HPV RL1 6 11 16 18 31 33 45 52 58 VLP VACCINE (YEAST) (GARDASIL 9) (dose 0.50 mL, frequency default to total; strength, route, lot # and expiration date were not reported) for prophylaxis. In 2026 (reported as recently, exact date was not provided), the pharmacist received a prescription for the second dose (dose 0.50 mL, frequency default to total; strength, route, lot # and expiration date were not reported) for prophylaxis (Inappropriate schedule of product administration). Confirmed no symptoms were reported. No additional adverse event (AE) /no product quality complaints (PQC) reported. Additional information is not expected.